Upexi Inc
UPXI8.150USD
+0.670+8.96%
Close 07/21, 16:00（ET）Quotes delayed by 15 min
11.66MMarket Cap
LossP/E TTM
More Details of Upexi Inc Company
Upexi, Inc. is a brand owner specialized in the development, manufacturing and distribution of consumer products. The Company focuses on direct-to-consumer and Amazon brands. The Company’s brands include LuckyTail, PRAX, Cure Mushrooms, Moonwlkr, Gumi Labs, and Upexi Distribution. LuckyTail products consist of its flagship nail grinder and healthy all-natural pet supplements. Gumi Labs manufactures gummies and other products supporting its health and wellness products, including those products manufactured with hemp ingredients. Upexi Distribution manages the warehousing and logistic needs of the Company and provides storage, consolidation, assembly, Amazon preparation, distribution and fulfilment services to its brands and its manufacturing operation.
Company Info
Ticker SymbolUPXI
Company nameUpexi Inc
IPO dateJun 24, 2021
Founded at2018
CEO- -
Number of employees64
Security typeOrdinary Share
Fiscal year-endJun 24
Address3030 Rocky Point Drive
CityTAMPA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code33607
Phone17013535425
Websitehttps://upexi.com/
Ticker SymbolUPXI
IPO dateJun 24, 2021
Founded at2018
Company Executives
Name
Name/Position
Position
Shareholding
Change
Allan Marshall ,
Allan Marshall ,
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
884.32K
+484.01%
Dr. Gene Salkind, M.D.
Dr. Gene Salkind, M.D.
Independent Director
Independent Director
365.13K
+194.70%
Mr. Andrew J. Norstrud
Mr. Andrew J. Norstrud
Chief Financial Officer, Director
Chief Financial Officer, Director
159.14K
+941.62%
Mr. Lawrence H. Dugan
Mr. Lawrence H. Dugan
Independent Director
Independent Director
--
--
Mr. Thomas Charles Williams
Mr. Thomas Charles Williams
Independent Director
Independent Director
--
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Name
Name/Position
Position
Shareholding
Change
Allan Marshall ,
Allan Marshall ,
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
884.32K
+484.01%
Dr. Gene Salkind, M.D.
Dr. Gene Salkind, M.D.
Independent Director
Independent Director
365.13K
+194.70%
Mr. Andrew J. Norstrud
Mr. Andrew J. Norstrud
Chief Financial Officer, Director
Chief Financial Officer, Director
159.14K
+941.62%
Mr. Lawrence H. Dugan
Mr. Lawrence H. Dugan
Independent Director
Independent Director
--
--
Mr. Thomas Charles Williams
Mr. Thomas Charles Williams
Independent Director
Independent Director
--
--
Mr. Valter Pinto
Mr. Valter Pinto
Investor Relations
Investor Relations
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q2
FY2025Q1
FY2024Q1
By BusinessUSD
Name
Revenue
Proportion
Internally manufactured
2.51M
62.68%
Contract manufactured
834.86K
20.84%
Purchased as finished goods
659.80K
16.47%
By RegionUSD
Name
Revenue
Proportion
United States of America
3.95M
98.66%
Other
53.69K
1.34%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Internally manufactured
2.51M
62.68%
Contract manufactured
834.86K
20.84%
Purchased as finished goods
659.80K
16.47%
Shareholding Stats
Updated: Fri, Jul 18
Updated: Fri, Jul 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Attestor Capital LLP
6.79%
GSR Growth Investments LP
4.58%
Novogratz (Michael E)
4.35%
Kathmere Capital Management
4.35%
Marshall (Allan)
1.76%
Other
78.17%
Shareholders
Shareholders
Proportion
Attestor Capital LLP
6.79%
GSR Growth Investments LP
4.58%
Novogratz (Michael E)
4.35%
Kathmere Capital Management
4.35%
Marshall (Allan)
1.76%
Other
78.17%
Shareholder Types
Shareholders
Proportion
Individual Investor
8.02%
Hedge Fund
6.79%
Corporation
4.58%
Investment Advisor
4.38%
Investment Advisor/Hedge Fund
0.04%
Other
76.19%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
42
6.37M
16.79%
+6.01M
2025Q1
42
311.78K
28.56%
-35.31K
2024Q4
42
307.62K
23.29%
-32.82K
2024Q3
40
303.51K
29.16%
-55.91K
2024Q2
40
319.39K
30.68%
-45.58K
2024Q1
42
328.34K
32.32%
-46.59K
2023Q4
42
319.26K
31.43%
-34.26K
2023Q3
40
369.15K
37.28%
-46.01K
2023Q2
44
368.80K
38.85%
-28.58K
2023Q1
40
400.82K
45.14%
-64.50K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
GSR Growth Investments LP
2.31M
6.08%
+2.31M
--
Apr 24, 2025
Novogratz (Michael E)
2.19M
5.78%
+2.19M
--
Apr 24, 2025
Marshall (Allan)
884.32K
2.33%
+732.89K
+484.01%
Apr 17, 2025
Rudick (Brian Benjamin)
438.60K
1.16%
+438.60K
--
May 23, 2025
Salkind (Gene)
365.13K
0.96%
+241.23K
+194.70%
Apr 17, 2025
Norstrud (Andrew J)
159.14K
0.42%
+143.86K
+941.62%
Apr 17, 2025
BMO Nesbitt Burns Inc.
10.01K
0.03%
--
--
Mar 31, 2025
View more
Related ETFs
Updated: Sun, Jul 6
Updated: Sun, Jul 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Sep 27, 2024
Merger
20<1
Sep 27, 2024
Merger
20<1
Sep 27, 2024
Merger
20<1
Sep 27, 2024
Merger
20<1
Date
Type
Ratio
Sep 27, 2024
Merger
20<1
Sep 27, 2024
Merger
20<1
Sep 27, 2024
Merger
20<1
Sep 27, 2024
Merger
20<1
